NFE2L2 and lip and oral cavity carcinoma: Furthermore, this study proposes a promising therapeutic strategy combining NRF2 inhibition with PDT to enhance treatment efficacy, enabling the reversal of OLK lesions to normalized mucosa or low-grade, low-risk lesions and reducing the risk of malignant transformation into oral cancer.